Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

PHRM

PharmaTher (PHRM)

PharmaTher Holdings Ltd
De:
Trier par:
 Showing the most relevant articles for your search:CSE:PHRM
DateHeureSourceTitreSymboleSociété
11/11/202116h00InvestorsHub NewsWirePharmaTher Announces Positive Research Results for Psilocybin Microneedle PatchCSE:PHRMPharmaTher Holdings Ltd
03/11/202113h03InvestorsHub NewsWirePharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle PatchCSE:PHRMPharmaTher Holdings Ltd
19/10/202113h07InvestorsHub NewsWirePharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine ProductsCSE:PHRMPharmaTher Holdings Ltd
13/10/202115h20InvestorsHub NewsWirePharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain SyndromeCSE:PHRMPharmaTher Holdings Ltd
21/09/202116h19InvestorsHub NewsWirePharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded FundCSE:PHRMPharmaTher Holdings Ltd
13/09/202115h03InvestorsHub NewsWirePharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022CSE:PHRMPharmaTher Holdings Ltd
04/08/202114h15InvestorsHub NewsWirePharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral SclerosisCSE:PHRMPharmaTher Holdings Ltd
21/07/202114h19InvestorsHub NewsWirePharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine FormulationCSE:PHRMPharmaTher Holdings Ltd
16/06/202117h14InvestorsHub NewsWirePharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat DepressionCSE:PHRMPharmaTher Holdings Ltd
25/05/202114h45InvestorsHub NewsWirePharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig's DiseaseCSE:PHRMPharmaTher Holdings Ltd
17/05/202114h02InvestorsHub NewsWirePharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson's DiseaseCSE:PHRMPharmaTher Holdings Ltd
27/04/202113h47InvestorsHub NewsWirePharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics..ContCSE:PHRMPharmaTher Holdings Ltd
20/04/202114h00InvestorsHub NewsWirePharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical TrialCSE:PHRMPharmaTher Holdings Ltd
15/04/202117h32InvestorsHub NewsWirePharmaTher Provides Update on Psychedelic Product ProgramsCSE:PHRMPharmaTher Holdings Ltd
02/03/202113h34InvestorsHub NewsWirePharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou....ContCSE:PHRMPharmaTher Holdings Ltd
17/02/202116h11InvestorsHub NewsWirePharmaTher Announces Sale of Psilocybin ProgramCSE:PHRMPharmaTher Holdings Ltd
04/02/202114h21InvestorsHub NewsWirePharmaTher Announces Successful Completion of Pre-IND Meeting with FDACSE:PHRMPharmaTher Holdings Ltd
01/02/202114h19InvestorsHub NewsWirePharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver KetamineCSE:PHRMPharmaTher Holdings Ltd
19/01/202114h07InvestorsHub NewsWirePharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine FormulationCSE:PHRMPharmaTher Holdings Ltd
 Showing the most relevant articles for your search:CSE:PHRM